FY2025 EPS Estimates for Immutep Limited (NASDAQ:IMMP) Increased by Analyst

Immutep Limited (NASDAQ:IMMP) – Research analysts at Capital One Financial lifted their FY2025 earnings per share estimates for shares of Immutep in a report issued on Tuesday, September 3rd. Capital One Financial analyst N. Quibria now forecasts that the biotechnology company will earn ($0.29) per share for the year, up from their previous estimate of ($0.31). Capital One Financial currently has a “Overweight” rating and a $10.00 target price on the stock. The consensus estimate for Immutep’s current full-year earnings is ($0.24) per share. Capital One Financial also issued estimates for Immutep’s FY2026 earnings at ($0.31) EPS, FY2027 earnings at ($0.32) EPS and FY2028 earnings at ($0.26) EPS.

Separately, Robert W. Baird dropped their price target on Immutep from $7.00 to $6.00 and set an “outperform” rating on the stock in a research note on Thursday, June 27th.

Immutep Stock Up 1.6 %

Shares of NASDAQ:IMMP opened at $2.57 on Friday. The business’s 50-day moving average is $2.14 and its 200 day moving average is $2.45. Immutep has a 1 year low of $1.58 and a 1 year high of $3.34.

Institutional Investors Weigh In On Immutep

Institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd purchased a new position in Immutep in the 2nd quarter worth $26,000. XY Capital Ltd purchased a new position in shares of Immutep in the second quarter worth about $105,000. Virtu Financial LLC lifted its holdings in shares of Immutep by 269.4% during the first quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 32,864 shares during the period. Oracle Investment Management Inc. boosted its position in Immutep by 9.4% in the first quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company’s stock valued at $1,316,000 after buying an additional 48,449 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Immutep by 15.4% in the 1st quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock valued at $82,000 after acquiring an additional 4,700 shares during the last quarter. 2.32% of the stock is currently owned by institutional investors and hedge funds.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.